Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.
about
Chronic myeloid leukemia: reminiscences and dreamsEuropean LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaChanging the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EUSafety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trLong-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.The choice of first-line chronic myelogenous leukemia treatment.TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsAnalyzing molecular response in chronic myeloid leukemia clinical trials: pitfalls and golden rules.HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence?Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.Update on emerging treatments for chronic myeloid leukemia.Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia.Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients.Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis.Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors.Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib.Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making.Comparable Outcomes of Patients Eligible versus Ineligible for SWOG Leukemia Studies.Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib.First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis
P2860
Q26748769-5D1F9A8B-E26C-433B-8E67-F6EA8C674895Q26749324-774FACD2-2839-4683-89A8-5B23C29B0045Q28086893-E2476E3D-484D-4824-A5A5-A7C3151A712EQ30891587-8E36208B-B1AE-49BE-AA7C-5B70D7003F13Q31033077-A70562B4-946D-4AAC-AA85-39FC49C291FEQ33434675-05636B85-1681-46F7-9745-59210A9F1807Q35221071-B992E2C6-2914-44B2-BE86-2DD9D1674A23Q37509428-A1511A4E-D32D-4339-951C-A7826662E564Q38262877-942E3675-E073-44CD-8118-68812FA09245Q38270419-25D7E1B4-F86F-4D46-8424-4725F2E6DF6EQ38392673-34E19C3D-A045-490A-A925-39A8EA47ED9AQ38397515-C7D8209B-EFF4-4792-B317-FF0D4B58F3B5Q38748512-09374EE6-0C5E-4397-8319-CE33C0EE2238Q39035188-94C82FF4-D4F6-4BF4-AD9E-D39274CCDEB8Q42391592-A0025E8E-E519-481F-8BF1-132BDD1AFAB8Q47096076-A3B6FB65-EDB7-419C-AE17-5EAA432AFEEAQ47659016-A8AFCC47-0BE0-422F-9BF3-AFE605480944Q48364277-F42CA4E0-D485-482F-BE48-8D2EAA79CA7FQ49244147-6F014401-EB68-46CD-BC03-778A14BD7081Q50997822-A625CD9C-6DEE-4ECD-97AE-8A38101ED77CQ52567954-4F19142E-4753-4060-A368-BAEC3A4518D3Q53832560-914FA00C-8192-4547-B3FC-E3C0467745F0Q54158097-01D41B7D-3D4B-4591-A607-1E513B4BFF35Q57069646-A985407C-38DA-45AA-8B83-59710004C9B4
P2860
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Imatinib 800 mg daily induces ...... ase chronic myeloid leukaemia.
@ast
Imatinib 800 mg daily induces ...... ase chronic myeloid leukaemia.
@en
Imatinib 800 mg daily induces ...... ase chronic myeloid leukaemia.
@nl
type
label
Imatinib 800 mg daily induces ...... ase chronic myeloid leukaemia.
@ast
Imatinib 800 mg daily induces ...... ase chronic myeloid leukaemia.
@en
Imatinib 800 mg daily induces ...... ase chronic myeloid leukaemia.
@nl
prefLabel
Imatinib 800 mg daily induces ...... ase chronic myeloid leukaemia.
@ast
Imatinib 800 mg daily induces ...... ase chronic myeloid leukaemia.
@en
Imatinib 800 mg daily induces ...... ase chronic myeloid leukaemia.
@nl
P2093
P2860
P50
P356
P1476
Imatinib 800 mg daily induces ...... ase chronic myeloid leukaemia.
@en
P2093
Jeffrey H Lipton
Jerald P Radich
Kenneth J Kopecky
Marilyn L Slovak
Michael W Deininger
Wendy Stock
P2860
P304
P356
10.1111/BJH.12618
P407
P50
P577
2013-11-04T00:00:00Z